The bacteria in the human stomach is called to be a good plant for biological drugs and thanks to modify some of the genes of other species, causing gastroenteritis. Using a pair that sounds unlikely, researchers Ammrika States and Switzerland have created the first bacterial methods to take full advantage of the glycoprotein found in the human body. This approach provides unprecedented sebelumnyaterhadap sugar control was recorded in protein and can further improve the performance of biological medicines.
"This method is a combination dapa provide an efficient way to produce glycoprotein home remedies, such as monoclonal antibodies," clearly Lai-Xi Wang from the University of Maryland, USA. As a glycoprotein, the monoclonal antiobodi ongoing activities may be inconsistent due to the polysaccharide glycan - or - that produce much. "Glycoprotein produced as a live mix," said Wang "Only a few of the glycoform that is very active." Glycosylating a homogeneous protein with an active glycan produce a more potent drug.
Escherichia coli is usually harmless, where they can destroy microbes have been used in industry to produce proteins, but the glycoprotein, where they can add the sugar memodulasikan. "In general, bacteria do not have proteins glycosylasi team," said Wang But once Mark Aebi, Swiss Federal Institute of Technology (ETH) in Zurich has found that the bacteria Campylobacter jejuni is dangerous not to have an unusual ability to paste sugar to proteins. Engineering and transfer equipment C. jejuni in E. glycosylasi coli and then used an enzyme to modify one part sugar to produce the protein was uniformly glycosylasi
Unfortunately, C. Jejuni glycoprotein produced normally trigger an immune response in the human body. This is because bacteria N-glucan, an alpha-linked oligosaccharides N-acetyl-galactosamine, which is attached to asparagine residues of proteins through bacillosamine aminosugar an unusual appeal that makes it not as glycan in humans. Aebi and Wang are the computer before transferring genes in E. glycosylasi coli, to change the sugar is first attached to asparagine in N-acetylglucosamine that is commonly found in our bodies. Then, using enzymatic methods in vitro, which decorate and replace residues of N-acetyl-galactosamine to the N-glycans that glycosylasi selected for "human" homogeneous.
"The ability to express proteins in E. coli is easier and cheaper," says Antonio Fairbanks, University of Canterbury, New Zealand. How to Fairbanks, who founded the company in the UK targeting drugs, Glycoform, said that while this method worked with glycoprotein C. jejuni had glycosylasi IgG antibodies in humans are generally a bit incomplete.
"This method is a combination dapa provide an efficient way to produce glycoprotein home remedies, such as monoclonal antibodies," clearly Lai-Xi Wang from the University of Maryland, USA. As a glycoprotein, the monoclonal antiobodi ongoing activities may be inconsistent due to the polysaccharide glycan - or - that produce much. "Glycoprotein produced as a live mix," said Wang "Only a few of the glycoform that is very active." Glycosylating a homogeneous protein with an active glycan produce a more potent drug.
Escherichia coli is usually harmless, where they can destroy microbes have been used in industry to produce proteins, but the glycoprotein, where they can add the sugar memodulasikan. "In general, bacteria do not have proteins glycosylasi team," said Wang But once Mark Aebi, Swiss Federal Institute of Technology (ETH) in Zurich has found that the bacteria Campylobacter jejuni is dangerous not to have an unusual ability to paste sugar to proteins. Engineering and transfer equipment C. jejuni in E. glycosylasi coli and then used an enzyme to modify one part sugar to produce the protein was uniformly glycosylasi
Unfortunately, C. Jejuni glycoprotein produced normally trigger an immune response in the human body. This is because bacteria N-glucan, an alpha-linked oligosaccharides N-acetyl-galactosamine, which is attached to asparagine residues of proteins through bacillosamine aminosugar an unusual appeal that makes it not as glycan in humans. Aebi and Wang are the computer before transferring genes in E. glycosylasi coli, to change the sugar is first attached to asparagine in N-acetylglucosamine that is commonly found in our bodies. Then, using enzymatic methods in vitro, which decorate and replace residues of N-acetyl-galactosamine to the N-glycans that glycosylasi selected for "human" homogeneous.
"The ability to express proteins in E. coli is easier and cheaper," says Antonio Fairbanks, University of Canterbury, New Zealand. How to Fairbanks, who founded the company in the UK targeting drugs, Glycoform, said that while this method worked with glycoprotein C. jejuni had glycosylasi IgG antibodies in humans are generally a bit incomplete.
No comments:
Post a Comment